5-HT2 ligands in the treatment of anxiety and depression

Author： Quesseveur Gaël Nguyen Hai T Gardier Alain M Guiard Bruno P

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.11, 2012-11, pp. : 1701-1725

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Potential of 5-HT2C Receptor Antagonists in the Treatment of Anxiety Disorders

Current Drug Targets-CNS & Neurological Disorders, Vol. 2, Iss. 6, 2003-12 ,pp. : 383-387

Bentham Science Publishers

Access to resources Recommend Favorite

5HT2C receptor agonists and antagonists in animal models of anxiety

By Martin J.R. Bouml s M. Jenck F. Kouml hler C. Moreau J.-L. Sleight A.J. Stadler H. Wichmann J.

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 209-209

Elsevier

Access to resources Recommend Favorite

5-HT2A Inverse-Agonists for the Treatment of Insomnia

Current Topics in Medicinal Chemistry, Vol. 8, Iss. 11, 2008-07 ,pp. : 969-976

Bentham Science Publishers

Access to resources Recommend Favorite

Transcriptional Dys-regulation in Anxiety and Major Depression: 5-HT1A Gene Promoter Architecture as a Therapeutic Opportunity

Current Pharmaceutical Design, Vol. 20, Iss. 23, 2014-05 ,pp. : 3738-3750

Bentham Science Publishers

Access to resources Recommend Favorite

Synthesis and pharmacological evaluation of novel 4-(4-fluorobenzoyl)piperidine derivatives as mixed 5-HT 1A /5-HT 2A /D 2 receptor ligands

By Diouf O. Carato P. Lesieur I. Rettori M.C. Caignard D.H.

European Journal of Medicinal Chemistry, Vol. 34, Iss. 1, 1999-01 ,pp. : 69-73

Elsevier

Access to resources Recommend Favorite